CSSi Appoints Dr. Ronald Bukowski to Newly Formed Medical and Clinical Advisory Board - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
CSSi Appoints Dr. Ronald Bukowski to Newly Formed Medical and Clinical Advisory Board

CSSi Appoints Dr. Ronald Bukowski to Newly Formed Medical and Clinical Advisory Board

PR Newswire

GLEN BURNIE, Md., June 9, 2014 /PRNewswire/ -- CSSi, the leader in patient recruitment solutions for the clinical research industry, recently announced the formation of the company's Medical and Clinical Advisory Board (MCAB) and the appointment of Ronald M. Bukowski, MD as its chairman.

Photo - http://photos.prnewswire.com/prnh/20140606/95194

The MCAB, with Dr. Bukowski's leadership, will help provide insight across a variety of therapeutic areas and set strategic goals for the advancement and development of CSSi's work within the clinical research industry to shorten the timelines of getting new drugs to market. Additionally, the MCAB will strive to identify best practices based on evidence and clinical guidelines to achieve optimum outcomes of research trials. The newly formed MCAB will continue to add industry renowned physicians and researchers who have been trailblazers in the field of clinical research.

Dr. Bukowski is an emeritus staff at the Taussig Cancer Center and the Cleveland Clinic Foundation. He was recently Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University and the Deputy Director of the Cleveland Clinic Taussig Cancer Center. He was the Director of the Experimental Therapeutics Program at the Cleveland Clinic Cancer Center, and held the James Zito Chair in Cancer Research from 2001 to 2008.  Dr. Bukowski is a fellow of the American College of Physicians and a member of numerous professional societies, including the American Society of Clinical Oncology, and the American Association of Cancer Research. He is a lifelong researcher with interests in new drug development and investigation, as well as biologic response modifiers and the biology of renal cell carcinoma. Currently, Dr. Bukowski is the chairman of the medical committee of the Kidney Cancer Association and chairman of its board of directors.

"The formation of our Medical and Clinical Advisory Board speaks to CSSi's long standing support and commitment towards bringing the highest quality of clinical research practices to the industry.  We are thrilled to welcome Dr. Bukowski as the chairman and founding member of this board. We eagerly anticipate that his experience and expert guidance will play a critical role in guiding our work and developing innovative products in all areas of the life sciences industry.  Our newly formed advisory board will allow us to strengthen our global relationships with strategic partners, sponsors and CROs, as well as regulatory authorities," stated Chris Trizna, President of CSSi. 

"I am thrilled to join the CSSi team," shared Dr. Ron Bukowski. "This company has been an important part of the patient recruitment landscape; I hope to help bring additional value to their current offerings, including medical insight into patient pathways, protocol analysis, enrollment feasibility and the identification of global regulatory challenges."

Additional physicians will be added in the near future, allowing for expansion of global regulatory specialties and therapeutic diversity which will reflect the international leadership position of CSSi in the patient recruitment industry.

About CSSi

CSSi delivers global patient recruitment solutions that ensure successful enrollment, on time, every time. Through its innovative enrollment planning and full-service patient recruitment solutions, CSSi is able to reduce the costs and timelines associated with recruitment of subjects for clinical studies.


Jennifer Whitlock 
P: 443-308-5803 
F: 410-553-0087 



blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document

Click here